Malaria is a life-threatening disease affecting people globally. It is spread by mosquitoes carrying Plasmodium parasites that infect and hide in red blood cells, making them difficult for the immune system to detect.
Organ transplant recipients with advanced cancer, an often overlooked group in cancer care, may benefit from immunotherapy drugs, according to a new study.
Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant laboratory experiments, scientists have uncovered how a pair of these lab-engineered molecules fight malaria.
Human exposure to toxic particles drives various diseases. Examples include gout, an acute arthritis driven by monosodium urate crystals, or MSUc; CPPD disease, another inflammatory joint disease driven by calcium pyrophosphate dihydrate crystals, or C…
A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown to be safe and effective in human trials. Acting like a “smart missile,” the dual-targeting radiopharmaceutical is designed to …
A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The results of the study suggest that combining this innovative tr…
A rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine. The finding adds to growing evidence that br…
New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that can last decades—in diagnosing lupus, an auto-immune condition.
Some cancers and chronic inflammatory diseases are treated with immunotherapies. These stimulate the patient’s immune system to recognize and destroy tumor cells. To improve such therapies, researchers are looking for mechanisms involved in triggering …
A Peter Mac-initiated clinical trial suggests a way to dramatically improve outcomes in patients with high-risk forms of large B-cell lymphoma, who otherwise have a 50% chance of cure from conventional therapy.
